Full text is available at the source.
The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study
Orlistat's effects on weight and blood fats in obese people with high cholesterol
AI simplified
Abstract
Orlistat treatment resulted in a 6.8% mean percentage weight loss after 24 weeks, compared to 3.8% in the placebo group.
- Orlistat was associated with a higher percentage of patients achieving clinically meaningful weight loss of ≥5% (64%) and ≥10% (23%) compared to placebo (39% and 13%, respectively).
- Significant reductions in total cholesterol (-11.9% vs -4.0%) and low-density lipoprotein cholesterol (LDL-C) (-17.6% vs -7.6%) were observed in the orlistat group compared to placebo.
- The change in LDL-C was more pronounced in patients treated with orlistat, suggesting a cholesterol-lowering effect independent of weight loss.
- In the subsequent open-label phase, patients who initially received placebo and were given orlistat experienced further reductions in weight, total cholesterol, and LDL-C.
- Orlistat was generally well tolerated, with a safety profile similar to placebo, though gastrointestinal events were reported more frequently in the orlistat group (64% vs 38%).
AI simplified